Abraham (Avri) Rubinstein is a Full Professor of Pharmaceutical Sciences at The Hebrew University of Jerusalem, Faculty of Medicine, School of Pharmacy Institute for Drug Research. After completing his M.Sc. degree (physical pharmacy) he joined the R&D division of Teva Pharmaceutical Industries, at which place he was promoted to head the Pharmacy R&D laboratory of the company. After 8 years in the industry he returned to the Hebrew University to complete his graduate studies (physical pharmacy and pharmacokinetics), spent two years as a postdoctoral fellow in the University of Wisconsin-Madison (GI physiology, motility and oral drug delivery) and joined the School of Pharmacy in Jerusalem as a faculty member. Apart of being a faculty member at the Hebrew University, Prof. Rubinstein was also an Adjunct Professor at the Rutgers School of Pharmacy, N.J., a member of the Board of Scientific Advisors of the Controlled Release Society of Bioactive Materials (CRS) and the President and a Founder of the Israeli Chapter of the Society (ICRS).
Professor Rubinstein is the author of more than 110 research articles, reviews and book chapters, 130 published presentations and 5 enabled patents. Three of the technologies he developed were purchased by start-up companies.
Prof. Rubinstein's research interests are focused on site-specific therapy and real-time diagnostics of inflammation and malignant processes in the gastrointestinal (GI) tract. It includes biodegradable polymers (modified polysaccharides) colon-specific drug delivery, site specific therapy of IBD by directed nano-vehicles, mechanistic understanding of affinity processes between saccharide-containing polymers and the intestinal epithelium and optimizing multimodal therapy by remotely eroding vehicles.
Due to his industrial background, Prof. Rubinstein expertise involves consulting activity in the design of bench-to-pilot procedures of drug delivery products.
Selected list of publications from the past 10 years
Tiwari S., Tirosh B. and Rubinstein A., Increasing the affinity of cationized polyacrylamide-paclitaxel nanoparticles towards colon cancer cells by a surface recognition peptide. Int. J. Pharm., 531: 281-291, 2017.
Bloch M., Yavin E., Nissan A., Ariel I., Kenett R., Brass D. and Rubinstein A., The effect of linker type and recognition peptide conjugation chemistry on tissue affinity and cytotoxicity of charged polyacrylamide. J. Contr. Rel., 257: 102-117, 2017
Kolevzon N., Hashoul D., Naik S., Rubinstein A. and Yavin E., Single point mutation detection in living cancer cells by far-red emitting PNA-FIT probes. Chem Commun, 52: 2405-2407, 2016.
Perlstein H., Turovsky T., Gimeson P., Cohen R., Rubinstein A., Danino D. and Barenholz Y., Thermotropic behavior of celecoxib-loaded beta-casein micelles: relevance to the improved bioavailability. Eur J Nanomed Eur. J. Nanomed, 7: 303-312, 2015.
Bloch M., Kenett R., Jablonowski L., Wheatley M., Yavin E. Rubinstein A., A multifactorial analysis of complex pharmaceutical platforms: an application of design of experiments (DoE) to targetable polyacrylamide and ultrasound contrast agents. Pol. Adv. Tech. 26: 898-905, 2015.
Moradov D., Shifrin H., Harel E., Nadler-Milbauer M., Weinstock M., Srebnik M. and Rubinstein A., The anti-inflammatory activity of a novel fused-cyclopentenone phosphonate and its potential in the local treatment of experimental colitis. Gastroenterol. Res. Pract., 2015: 1-10, 2015.
Bloch M., Jablonowski L., Yavin E., Moradov D., Djavsarov I., Nyska A., Wheatley M. and Rubinstein A., Multi-modal detection of colon malignancy by NIR-tagged recognition polymers and ultrasound contrast agents. Int. J. Pharm., 478: 504-516, 2015.
Perlstein H., Bavli Y., Turovsky T., Rubinstein A., Danino D., Stepensky D. and Barenholz Y., Beta-casein nanocarriers of celecoxib for improved oral bioavailability. Eur. J. Nanomed., 6: 217-226 2014.
Kam Y., Rubinstein A., Naik S., Djavsarov I., Halle D., Ariel I., Gure A. O., Stojadinovic A., Pan H., Tsivin V., Nissan A. and Yavin E., Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beacons. Cancer Letters, 352: 90-96, 2014.
Bloch M., Kam Y., Yavin E., Moradov D., Nissan A., Ariel I. and Rubinstein A., The relative roles of charge and a recognition peptide in luminal targeting of colorectal cancer by fluorescent polyacrylamide. Eur. J. Pharm. Sci., 47: 904-913, 2012
Moradov D., Rubinstein A., Gelman D. and Srebnik M., Molybdenum-mediated deconjugation of α,β-unsaturated fusedcyclopentenone phosphonate. Synthesis, 44: 1258-1262, 2012.
Smoum R., Rubinstein A., Dembitsky V. M. and Srebnik M., Boron containing compounds as protease inhibitors. Chem. Rev., 112: 5156-5220, 2012.
Kam Y., Rubinstein A., Nissan A., Halle D. and Yavin E., Detection of endogenous k-RAS mRNA in living cells at a single base resolution by a PNA molecular beacon. Molecular Pharm, 9: 685-693, 2012.
Khazanov E., Yavin E., Pascal A., Nissan A., Kohl Y., Reimann-Zawadzki M., and Rubinstein A., Detecting a secreted gastric cancer biomarker molecule by targeted nanoparticles for real-time diagnostics. Phram. Res. 29: 983-993, 2012.
Nadler-Milbauer M., Apter L., Haupt Y., Haupt S., Barenholz Y., Minko T. and Rubinstein A., Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. J. Drug Target., 19: 859-873, 2011.
Harel E., Rubinstein A., Nissan A., Khazanov E., Nadler-Milbauer M., Barenholz Y. and Tirosh B., Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa. PLoS ONE, 6(9): e24202, 2011.
Harel E., Rubinstein A., Chen W., Breuer E. and Tirosh B., Aminoalkylcarbamoyl-phosphonates reduce TNF release from activated immune cells. Bioorgan. Med. Chem. Lett., 20: 6518-6523, 2010.
Khazanov E., Emmanuel N., Azab A.K., Barenholz Y., Yavin E. and Rubinstein A., Specific detection of gastric -antitrypsin by immobilized trypsin on polyHEMA films. Molecular Pharm., 7: 944-952, 2010.
Tirosh B., Khatib N., Barenholz Y., Nissan A. and Rubinstein A., Transferrin as a luminal target for negatively-charged liposomes in the inflamed colonic mucosa. Molecular Pharm., 6: 1083-1091, 2009.
Nadler-Milbauer M, Azab A. K., Kleinstern J., Barenholz Y. and Rubinstein A., In vitro and in vivo analysis of pulsatile biodegradation of mucoadhesive hydrogels. J. Drug Del. Sci. Tech., 14: 247-255, 2009.
Moradov D., Al Quntar A. A., Youssef M., Smoum R., Shurki A., Rubinstein A. and Srebnik M., Mo(CO)6 ¬-mediated intramolecular Pauson-Khand reaction of substituted diethyl 3-allyloxy-1-propynylphosphonates. J. Org. Chem., 74: 1029-1033, 2009.
Azab A. K., Kleinstern J., Srebnik M. and Rubinstein A., The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers. Pharm. Res., 25: 379-386, 2008.
Azab A. K., Kleinstern J., Doviner V., Orkin B., Srebnik M., Nissan A. and Rubinstein A., Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I –norcholesterol. J. Contr. Rel., 123: 116-122, 2007.
Azab A. K., Doviner V., Orkin B., Kleinstern J., Srebnik M., Nissan A. and Rubinstein A., Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat. J. Biomed. Mater. Res. A, 83: 414-422, 2007.
Haupt S., Kleinstern J., Haupt Y. and Rubinstein A., Celecoxib can induce cell death independently of COX-2, p53, Mdm2, c-Abl and reactive oxygen species. Anti Cancer Drugs, 17: 609-619, 2006.
Smuom R., Rubinstein A. and Srebnik M., Chitosan-pentaglycine-phenylboronic acid conjugate: a potential colon-specific platform of calcitonin. Bioconjug. Chem., 17: 1000-1007, 2006.
Haupt S., Zioni T., Gati I., Kleinstern J., and Rubinstein A., Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur. J. Pharm. Sci., 28: 204-211, 2006.
Jubeh T., Nadler-Mirelbaum M., Barenholtz Y. and Rubinstein A., Local treatment of experimental colitis in the rat by adhesive liposomes of catalase, TMN and SOD. J. Drug Target., 14: 155-163, 2006.
Azab A. K., Orkin B., Doviner D., Nissan A., Klien M., Srebnik M. and Rubinstein A., Crosslinked chitosan implants as potential degradable devices for brachytherapy: in vitro and in vivo analysis. J. Contr. Rel., 111: 281-289, 2006.
Review articles & Book Chapters
Rubinstein A. , Nanoparticles in the gastrointestinal tract, in: Torchilin V.P. (ed) Handbook of Nanobiomedical Research: Fundamentals, Applications and Recent Developments, Part II: Applications in Therapy; Frontiers of Nanobiomedical Research series, Yarmush M. L. and Shi D. (eds), World Scientific Publishing, N.J., 2014, pp. 115-151.
Nadler-Milbauer M., Kam Y. and Rubinstein A., Orally administered drug delivery systems to the colon, in: Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice, Wen H. and Park K. (Eds), John Wiley & Sons, NJ, 2010, pp. 225-243.
Abutbul E. and Rubinstein A., Colon-targeted delivery system, in: Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development, Morishita M. and Park K. (Eds), Informa Healthcare, NY, 2009, pp. 138-171.
Rubinstein A., Gastrointestinal anatomy, physiology and permeation pathways. In: Touitou E. and Barry B. W. (Eds.), Enhancement in Drug Delivery, CRC Press, 2007, Boca Raton, pp. 3-37.
Rubinstein A., Colonic drug delivery. Drug Discov. Today: Technol., 2: 33-37, 2005.